HI SCR215

Request Department of Health to establish a Medicinal Psychedelics Right-to-Try Task Force to explore creating a program allowing qualifying terminally ill patients access to non-FDA-approved psychedelic drugs, including psilocybin and psilocin.

Task force must examine federal and state laws, eligible psychedelic drugs, patient qualification criteria, drug distribution methods, patient costs, insurance coverage, and statutory protections for patients and providers.

Task force membership includes Director of Health (chair), Attorney General, University of Hawaii faculty, legislative committee chairs, clinical practitioners, and representatives from Drug Policy Forum of Hawaii, Clarity Project, Hawaii Psychiatric Medical Association, and psychedelics industry.

Task force must submit preliminary report to Legislature no later than 20 days before Regular Session of 2024 and final report with proposed legislation no later than 20 days before Regular Session of 2025.

Task force dissolves July 1, 2025.